AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
On Nov. 23, 2020, AstraZeneca announced positive high-level results from an interim analysis of clinical trials of AZD1222…
On Nov. 23, 2020, AstraZeneca announced positive high-level results from an interim analysis of clinical trials of AZD1222…
On Nov. 23, 2020, the University of Oxford, in collaboration with AstraZeneca, announced interim trial data from its…
On Nov. 20, 2020, the ‘European Food Safety Authority reported that within the past month more than 300…
On Nov. 19, 2020, the University of Oxford announced that the ChAdOx1 nCov-2019 coronavirus vaccine had been shown…
On Nov. 19, 2020, Medigen Vaccine Biologics announced that preclinical results of their COVID-19 vaccine candidate had been…
On Nov. 19, 2020, ApiJect Systems, a public benefit corporatio, announced that it had been approved by the…
On Nov. 18, 2020, Pfizer and BioNTech announced that, after conducting the final efficacy analysis in their ongoing…
On Nov. 17, 2020, CureVac announced that it had accelerated the expansion of its manufacturing network to deliver…
On Nov. 17, 2020, Moderna announced a supply agreement with the government of the United Kingdom (UK) to…
On Nov. 17, 2020, Celdara Medical announced that the National Institute of Allergy and Infectious Disease (NIAID) of…
On Nov. 16, 2020, Biological E. Limited (BE), a Hyderabad-based vaccines and pharmaceutical company, Dynavax Technologies, and Baylor…
On Nov. 16, 2020, Moderna announced new data showing that mRNA-1273, its COVID-19 vaccine candidate, remained stable at…
On Nov. 16, 2020, Tonix Pharmaceuticals announced preliminary results following vaccination of non-human primates with TNX-1800 (modified horsepox…
On Nov. 16, 2020, BioNTech and Shanghai Fosun Pharmaceutica announced that the China National Medical Products Administration had…
On Nov. 16, 2020, INOVIO announced that it had received clearance from the the U.S. Food & Drug…
On Nov. 16, 2020, Moderna announced that the European Medicines Agency (EMA) human medicines committee (CHMP) had started…
On Nov. 16, 2020, the UK Department for Health and Social Care Testing Innovation Fund announced £12.2M funding…
On Nov. 15, 2020, an independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of…
On Nov. 15, 2020, Johnson & Johnson announced that it continued to enroll and vaccinate study participants for…
On Nov. 13, 2020, Moderna announced that Swissmedic had started a rolling review of mRNA-1273, the Company’s vaccine…
On Nov. 12, 2020, CureVac announced that its mRNA-based COVID-19 vaccine candidate, CVnCoV, remained stable and within defined…
On Nov. 12, 2020, the Bill & Melinda Gates Foundation announced new commitments totaling $70 million to global…
On Nov. 12, 2020 Vaxart announced additional results from its Hamster Challenge Study. The study evaluated Vaxartメs recombinant…
On Nov. 11, 2020, Sorrento Therapeutics announced that it was filing an investigational new drug application (IND) for…
On Nov. 11, 2020, the Serum Institute of India (SII) and Indian Council of Medical Research (ICMR) announced…
On Nov. 11, 2020, Moderna announced that it had completed case accrual for the first interim analysis of…
On Nov. 11, 2020, Pfizer and BioNTech announced that they had reached an agreement with the European Commission…
On Nov. 19, 2020, Medigen Vaccine Biologics and BlueWillow Biologics announced a partnership to develop S-2P-NE-01, a nasal…
On Nov. 10, 2020, ImmunityBio and NantKwest, a clinical-stage, natural killer cell-based therapeutics company, announced they had administered…
On Nov. 10, 2020, Altimmune announced an agreement with Lonza for the manufacturing of AdCOVIDル, Altimmuneメs next-generation, single-dose…